PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jan 31, 2018
Filed with the SEC on Mar 19, 2018 and accepted by EDGAR at Mar 19, 2018, 16:37 ET.
Management's discussion and analysis
As filed, 16,546 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (“Report”) includes “forward-looking statements” within the meaning of the federal securities laws. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Report, including any projections of earnings, revenue or other financial items, any statements regarding the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, any statements regarding expected benefits from any transactions and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by use of terminology such as “may,” “will,” “should,” “believes,” “intends,” “expects,” “plans,” “anticipates,” “estimates,” “goal,” “aim,” “potential” or “continue,” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained in this Report are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. Thus, investors should refer to and carefully review information in future documents we file with the Commission. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risk and uncertainties, including, but not limited to, the risk factors set forth in “Part I, Item 1A – Risk Factors” set forth in our Form 10-K for the year ended April 30, 2017 and for the other reasons described elsewhere in this Report
All forward- looking statements and reasons why results may differ included in this Report are made as of the date hereof, and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this Report, the “Company,” “we,” “us” and “our” refer to PharmaCyte Biotech, Inc., a Nevada corporation, and, where appropriate, its subsidiaries.
Overview
We are a clinical stage biotechnology company focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, non-metastatic inoperable pancreatic cancer, and diabetes will be developed.
We are developing therapies for pancreatic and other solid cancerous tumors by using the encapsulation of live cells which are surgically implanted at appropriate sites in the body to enable the delivery of a cancer-killing chemotherapy drug at the source of the cancer. We are working on our IND to submit to the United States Food and Drug Administration (“FDA”) so that we can commence a clinical trial involving locally advanced, inoperable non-metastatic pancreatic cancer. Based on advice from our consulting oncologists, our Chief Medical Officer and our Advisory Board regarding our planned trial design, we have determined that the data contained in previous clinical trial reports are not enough to fully support a Phase 3 pivotal trial. Therefore, we are designing a Phase 2b clinical trial that, if successful, we believe will provide the information necessary for a successful Phase 3 pivotal trial and possible accelerated approval by the FDA.
We are also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. The Company’s diabetes therapy consists of encapsulating genetically modified human cells and/or beta islet cells using the Cell-in-a-Box® technology and then implanting them in the body to act as a bio-artificial pancreas for insulin production.
In addition, we are examining ways to exploit the benefits of the Cell-in-a-Box® technology to develop therapies for cancer based upon the constituents of the Cannabis plant, known as “Cannabinoids.”
Performance Indicators
Non-financial performance indicators used by management to manage and assess how the business is progressing include, but are not limited to, the ability to: (i) acquire appropriate funding for all aspects of our operations; (ii) acquire and complete necessary contracts; (iii) complete activities for producing cells and having them encapsulated for the planned preclinical studies and clinical trials; (iv) have regulatory work completed to enable studies and trials to be submitted to regulatory agencies; (v) initiate all purity and toxicology cellular assessments; and (vi) ensure the manufacture of encapsulated cells in accordance with current good manufacturing procedures (“cGMP”) to use in our clinical trials.
There are numerous factors required to be completed successfully to ensure our final product candidates are ready for use in our clinical trials. Therefore, the effects of material transactions with related parties and certain other parties to the extent necessary for such an undertaking may have substantial effects on both the timeliness and success of our current and prospective financial position and operating results. Nonetheless, we are actively working to ensure strong ties and interactions to minimize the inherent risks regarding success. From our assessments to date, we do not believe there are factors which will cause materially different amounts to be reported than those presented in this Report and aim to assess this regularly to provide the most accurate information to our shareholders.
Results of Operations
Three and nine months ended January 31, 2018 compared to three and nine months ended January 31, 2017
Revenue
We had no revenues in the three and nine months ended January 31, 2018 and 2017.
Operating Expenses and Loss from Operations
The following table summarize our operating expenses and loss from operations for the three and nine months ended January 31, 2018 and 2017, respectively:
| Three Months Ended January 31, 2018 | 2017 | Nine Months Ended January 31, 2018 | 2017 |
|---|---|---|---|
| $2,030,660 | $1,282,015 | $5,533,373 | $3,287,607 |
The total operating expenses for the three-month period ended January 31, 2018 increased by $748,645 from the three months ended January 31, 2017. The increase is attributable to an increase in research and development cost of $222,847, an increase in director fees of $22,093, an increase in compensation expense of $239,445, a decrease in legal and professional expense of $36,762 and an increase in general and administrative expenses of $301,022. The increase in general and administrative expenses was mainly attributable to an increase in consulting and travel expenses.
The total operating expenses for the nine-month period ended January 31, 2018 increased by $2,245,766 from the nine months ended January 31, 2017. The increase is attributable to an increase in research and development cost of $737,203, an increase in director fees of $182,574, an increase in compensation expense of $489,914, an increase in legal and professional expanse of $56,011 and an increase in general and administrative expenses of $780,064. The increase in general and administrative expenses was mainly attributable to an increase in consulting and travel expenses.
Director fees for the three months ended January 31, 2018 increased by $22,093 from the three months ended January 31, 2017. The increase is attributable to an increase in the number of independent directors. Pursuant to the agreements we have entered into with our independent directors we pay a director compensation fee of $12,500 per quarter. Board compensation for non-independent directors is included in the amounts they receive under their respective executive compensation agreement.
Director fees for the nine months ended January 31, 2018 increased by $182,574 from the nine months ended January 31, 2017. The increase is attributable to an increase in the number of independent directors. Pursuant to the agreements we have entered into with our independent directors we pay a director compensation fee of $12,500 per quarter. The independent directors were awarded stock grants and stock options during the nine months ended January 31, 2018 in the amount of $64,827. Board compensation for non-independent directors is included in the amounts they receive under their respective executive compensation agreement.
Other income (expense), net
The following table sets forth our other income (expense), net for the three and nine months ended January 31, 2018 and 2017:
| Three Months Ended January 31, 2018 | 2017 | Nine Months Ended January 31, 2018 | 2017 |
|---|---|---|---|
| $– | $(131) | $– | $(1,056) |
Total other income (expense), net, for the three months ended January 31, 2018 decreased by the amount of $131 from the three months ended January 31, 2017. The decrease is attributable to the reduction of interest expense in the amount of $131.
Total other income (expense), net, for the nine months ended January 31, 2018 decreased by the amount of $1,056 from the nine months ended January 31, 2017. The decrease is attributable to the reduction of interest expense in the amount of $1,056.
Discussion of Operating, Investing and Financing Activities
The following table presents a summary of our sources and uses of cash for the nine months ended January 31, 2018 and 2017, respectively:
| Nine Months Ended January 31, 2018 | January 31, 2017 | |
|---|---|---|
| Net cash used in operating activities: | $(3,704,812) | $(2,538,575) |
| Net cash used in investing activities: | $– | $– |
| Net cash provided by financing activities: | $1,751,409 | $3,080,883 |
| Effect of currency rate exchange | $(2,979) | $1,138 |
| Net increase (decrease) in cash | $(1,956,382) | $543,446 |
Operating Activities:
The cash used in operating activities for the nine months ended January 31, 2018 is a result of our net losses, offset by securities issued for services and compensation, a decrease to prepaid expenses and decreases to accounts payable offset by an increase in accrued expenses and an increase in term sheet agreement liability. The cash used in operating activities for the nine months ended January 31, 2017 is a result of our net losses: (i) offset by an increase in stock issued, decreases to prepaid expenses, accounts payable and accrued expenses; and (ii) decreased by the reduction in license agreement liability.
Investing Activities:
There were no investing activities in the nine months ended January 31, 2018 and 2017.
Financing Activities:
The cash provided from financing activities is mainly attributable to the proceeds from the sale of our common stock.
Liquidity and Capital Resources
As of January 31, 2018, our cash totaled approximately $1.5 million, compared to approximately $3.5 million at April 30, 2017. Working capital was approximately $709,000 at January 31, 2018 and approximately $3.0 million at April 30, 2017. The decrease in cash is attributable to proceeds from the sale of our common stock, net of the increase in our operating expenses.
We believe that our cash on hand as of January 31, 2018, the sales of registered and unregistered shares of our common stock and any public offerings of common stock in which we may engage will provide sufficient capital to meet our capital requirements and to fund our operations through March 31, 2019. We plan to pursue additional funding opportunities in connection with planning for and conducting our Phase 2b clinical trial in LAPC. Among others, we intend on continuing the sale of our common stock to raise capital to fund these activities and for working capital for corporate purposes, if necessary.
Off-Balance Sheet Arrangements
Except as described below, we have no off-balance sheet arrangements that could have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.
The future royalty payments under the APA, the Diabetes License Agreement and the Cannabis License Agreement (to be amended pursuant to the Term Sheet) are: (i) 4% royalty on all gross sales by us; and (ii) 20% royalty on gross revenues we receive from sublicensing, provided, however, that in the event the amounts received by us from sublicensees is 4% or less of sublicensees’ gross sales, Austrianova will receive 50% of what we receive (up to 2%) and then additionally 20% of any amount we receives over 4%.
The future royalty, milestone and patent prosecution costs under the Melligen Cell License Agreement are: (i) 6% royalty on gross sales and 25% royalty on sublicense gross sales; (ii) milestone payments of $50,000 after the first preclinical study, $100,000 after the successful conclusion of a Phase 1 clinical trial, $450,000 after the successful conclusion of a Phase 2 clinical trial and $3,000,000 after the successful conclusion of a Phase 3 clinical trial; and (iii) 15% of the costs paid by UTS to prosecute and maintain patents related to the licensed intellectual property.
Contractual Obligations
The following table presents certain payments due by us as of January 31, 2018 with respect to our known contractual obligations:
Payments due by period
| Contractual Obligations | Total | Less than 1 Year | 1-3 Years | 3-5 Years | More than 5 Years |
|---|---|---|---|---|---|
| Capital Leases | $– | $– | $– | $– | $– |
| Operating Leases | 52,383 | 33,084 | 19,299 | – | – |
| Purchase Obligations | – | – | – | – | – |
| Other Long-Term Liabilities Reflected on the Company’s Balance Sheet under U.S. GAAP | – | – | – | – | – |
| Total | $52,383 | $33,084 | $19,299 | $– | $– |
As of January 31, 2018, we leased office space in Laguna Hills, California under a lease ending August 31, 2019.
Critical Accounting Estimates and Policies
Our Condensed Consolidated Financial Statements are prepared in accordance with U.S. GAAP. In connection with their preparation, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our Condensed Consolidated Financial Statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates and such differences could be material.
We discuss our critical accounting estimates and policies in Part II, Item 7. "Management’s Discussion and Analysis of Financial Condition and Results of Operations" our Annual Report on Form 10-K for the year ended April 30, 2017. There has been no material change in our critical accounting estimates and policies since April 30, 2017.
New Accounting Pronouncements
For a discussion of all recently adopted and recently issued but not yet adopted accounting pronouncements, see Note 3 “Summary of Significant Accounting Policies” of the Notes to our Condensed Consolidated Financial Statements contained in this Report.
Available Information
Our website is located at www.PharmaCyte.com (http://www.PharmaCyte.com). In addition, all of our filings submitted to the Commission, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all of our other reports and statements are available on the Commission’s web site at www.sec.gov (http://www.sec.gov). Such filings are also available for download free of charge on our website. The contents of the website are not, and are not intended to be, incorporated by reference into this Report or any other report or document filed or furnished by us, and any reference to the websites are intended to be inactive textual references only.
Market risk
As filed, 1,736 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are exposed to market risks, which may result in potential losses arising from adverse changes in, among other things, foreign exchange rates. We have not taken steps to try and manage foreign exchange rate fluctuations. We do not enter into derivatives or other financial instruments for trading or speculative purposes to manage this risk. As indicated below, we do not believe we are exposed to material market risk with respect to our cash.
We currently have no operations outside the United States, but we have contracted with a Austrianova to manufacture our encapsulated live cell product in Singapore for preclinical studies and in Thailand for clinical trials. Manufacturing and research costs related to these activities are paid for in a combination of U.S. dollars and local currencies. Accordingly, we are subject to limited foreign currency exchange rate risk. It is not possible to estimate with any degree of accuracy the degree of this risk on a percentage basis. As of January 31, 2018, we do not believe foreign currency exchange rate risk is a substantial risk at this time due to the limited extent of our operations; however, if we conduct additional clinical trials and seek to manufacture a more significant portion of our product candidates outside of the United States in the future, we could incur significant foreign currency exchange rate risk.
As of January 31, 2018, we had cash of approximately $1.5 million. We do not engage in any hedging activities against changes in interest rates or foreign currency exchange rates. Because of the short-term nature of our cash, we do not believe that an immediate 10% increase in interest rates would have any significant impact on the fair value of our cash.
Controls and procedures
As filed, 6,980 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our Chief Executive Officer, President and General Counsel, as our principal executive officer (“Chief Executive Officer”), and our Chief Financial Officer, as our principal financial officer (“Chief Financial Officer”), evaluated the effectiveness of our “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Disclosure controls and procedures are designed to ensure that the information required to be disclosed in the reports that we file or submit to the Commission pursuant to the Exchange Act are recorded, processed, summarized and reported within the period specified by the Commission’s rules and forms and are accumulated and communicated to our management, including our Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosures. Based upon this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of January 31, 2018, our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting.
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Also, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Management’s Evaluation of Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as that term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.
Under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting as of January 31, 2018 based on the criteria outlined in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and identified the following material weaknesses in internal control over financial reporting:
- Ineffective communication of internal information with management and members of our Board. We are remediating this weakness by having regularly scheduled meetings with our Board, including our Audit Committee, on at least a quarterly basis. We have implemented management meetings to discuss the status of Company events and improve communication among members of our management.
- Insufficient procedures and control documentation to implement control procedures. We have undertaken a review process to develop procedures to provide ample review time of financial information by qualified accounting and finance personnel as well as management. We are still implementing this process and will require more time to fully implement. We will continue to address this issue.
- Insufficient segregation of duties of the Chief Financial Officer. We have delegated some of the duties of our Chief Financial Officer to other personnel within the Company.
- Insufficient information technology controls and documentation. We currently use accounting software which we have determined is inadequate to provide strong controls. We are in the process of initiating a review process to fully evaluate the deficiencies in our technology controls and documentation. Based upon the results of such a review process, we will implement required remediation measures.
Because of these material weaknesses, our Chief Executive Officer and our Chief Financial Officer concluded that, as of January 31, 2018, our internal control over financial reporting was not effective based on the COSO criteria.
We have begun the process of investigating new procedures and controls for fiscal year 2018. We plan to make changes to our procedures and controls that we believe are reasonably likely to strengthen and materially affect our internal control over financial reporting.
Prior to the remediation of these material weaknesses, there remains risk that the processes and procedures on which we currently rely will fail to be sufficiently effective, which could result in material misstatement of our financial position or results of operations and require a restatement. Moreover, because of the inherent limitations in all control systems, no evaluation of controls-even where we conclude the controls are operating effectively-can provide absolute assurance that all control issues, including instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, our control systems, as we develop them, may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected and could be material to our financial statements.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 2,947 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Form 10-K. The information set forth therein and in this Report could materially affect our business, financial position and results of operations. There are no material changes from the risk factors set forth the 10-K, except as follows:
The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.
On December 22, 2017, President Trump signed into law the final version of the tax reform bill commonly known as the “Tax Cuts and Jobs Act,” or the TCJA, that significantly reforms the Internal Revenue Code of 1986, as amended, with many of its provisions effective for tax years beginning on or after January 1, 2018. The TCJA, among other things, contains significant changes to corporate taxation, including a permanent reduction of the corporate income tax rate, a partial limitation on the deductibility of business interest expense, a limitation of the deduction for net operating loss carryforwards to 80% of current year taxable income, an indefinite net operating loss carryforward and the elimination of the two-year net operating loss carryback, temporary, immediate expensing for certain new investments , and the modification or repeal of many business deductions and credits. We continue to examine the impact this tax reform legislation may have on our business. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the TCJA is uncertain and our business and financial condition could be adversely affected. The impact of this reform on our stockholders is uncertain. Stockholders should consult with their tax advisors regarding the effect of the TCJA and other potential changes to the U.S. Federal tax laws on them.
Our plan to first pursue a Phase 2b clinical trial before a pivotal Phase 3 trial will likely result in additional costs to us and resultant delays in the FDA review process and any future commercialization and marketing, if regulatory approval is obtained.
Based on advice from our consulting oncologists, our Chief Medical Officer and our Advisory Board regarding our planned trial design, we have determined that the data contained in previous clinical trial reports using the Cell-in-a-Box® technology are not enough to fully support a Phase 3 pivotal trial. Therefore, we are designing a Phase 2b clinical trial that, if successful, we believe will provide the information necessary for a successful Phase 3 pivotal trial and possible accelerated approval. Our determination to first conduct a Phase 2b clinical trial before conducting a pivotal Phase 3 clinical trial will likely result in additional costs to us and resultant delays in the regulatory review process and any future commercialization and marketing, if regulatory approval is obtained.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-11-01 to 2018-01-31 | $0 | us-gaap:Revenues |
| Revenue | 9 months2017-05-01 to 2018-01-31 | $0 | us-gaap:Revenues |
| Research and development | 3 months2017-11-01 to 2018-01-31 | $802.6k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-05-01 to 2018-01-31 | $1.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-11-01 to 2018-01-31 | −$2.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-05-01 to 2018-01-31 | −$5.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-11-01 to 2018-01-31 | $0 | us-gaap:InterestExpense |
| Interest expense | 9 months2017-05-01 to 2018-01-31 | $0 | us-gaap:InterestExpense |
| Net income | 3 months2017-11-01 to 2018-01-31 | −$2.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-05-01 to 2018-01-31 | −$5.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-11-01 to 2018-01-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2017-05-01 to 2018-01-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2017-11-01 to 2018-01-31 | 975,848,246 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-05-01 to 2018-01-31 | 958,198,483 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-05-01 to 2018-01-31 | −$3.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2018-01-31 | $1.5m | us-gaap:Cash |
| Current assets | At period end2018-01-31 | $1.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-01-31 | $6.7m | us-gaap:Assets |
| Current liabilities | At period end2018-01-31 | $887.2k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-01-31 | $887.2k | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-01-31 | $5.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001683168-18-000720. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.